Blackrock Inc vs Mesoblast Limited — how do they compare? Blackrock Inc trades at $1,144.15 (market cap $175.22B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Blackrock Inc is far larger — about 81.1× Mesoblast Limited's market cap, and Blackrock Inc pays a 2.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BLK | MESO | |
|---|---|---|
Market Cap | $175.22B | $2.16B |
Volume | 641,547 | — |
Sector | Financials | Technology |
52-Week High | $1.20K | $20.96 |
52-Week Low | $922.90 | $12.88 |
Enterprise Value | $176.32B | $2.17B |
Dividend Yield | 2.03% | — |
Signals from Pluang's Aura AI — not financial advice
BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.
BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Latest headlines on both assets
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →